Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study

被引：0
|
作者：
Longo, Raffaele [1 ]
Thiebaut, Victoire [1 ]
Legros, Pierre-Olivier [1 ]
Campitiello, Marco [1 ]
Plastino, Francesca [1 ]
Goetz, Christophe [2 ]
Margineanu, Bogdan [3 ]
Pujois, Julie [3 ]
Gunther, Michel [3 ]
Egea, Julie [1 ]
Wendel, Chloe [1 ]
机构：
[1] CHR Metz Thionville, Div Med Oncol, 1 Allee Chateau, F-57085 Ars Laquenexy, France
[2] CHR Metz Thionville, Clin Res Support Unit, Ars Laquenexy, France
[3] CHR Metz Thionville, Div Gynecol, Ars Laquenexy, France
来源：
ACTA ONCOLOGICA | 2022年 / 61卷 / 11期
关键词：
OPEN-LABEL; PLUS TRASTUZUMAB; LAPATINIB; SAFETY; CHEMOTHERAPY; EFFICACY; RECOMMENDATIONS; MULTICENTER; PERTUZUMAB; THERAPY;
D O I：
10.1080/0284186X.2022.2132115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1394 / 1399
页数：6
相关论文
共 50 条
  • [1] Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
    Tiwari, Shruti R.
    Mishra, Prasun
    Raska, Paola
    Calhoun, Benjamin
    Abraham, Jame
    Moore, Halle
    Budd, G. Thomas
    Fanning, Alicia
    Valente, Stephanie
    Stewart, Robyn
    Grobmyer, Stephen R.
    Montero, Alberto J.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 189 - 193
  • [2] Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
    Shruti R. Tiwari
    Prasun Mishra
    Paola Raska
    Benjamin Calhoun
    Jame Abraham
    Halle Moore
    G. Thomas Budd
    Alicia Fanning
    Stephanie Valente
    Robyn Stewart
    Stephen R. Grobmyer
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2016, 158 : 189 - 193
  • [3] Inflammatory HER2-positive breast cancer
    Dirix, Luc Y.
    Vermeulen, Peter B.
    LANCET ONCOLOGY, 2012, 13 (04) : 324 - 326
  • [4] Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?
    Mazzotta, Marco
    Barba, Maddalena
    Pizzuti, Laura
    Vici, Patrizia
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S281 - S284
  • [5] Neoadjuvant therapy for triple negative and HER2-positive early breast cancer
    Harbeck, Nadia
    Gluz, Oleg
    BREAST, 2017, 34 : S99 - S103
  • [6] Is there a role for immunotherapy in HER2-positive breast cancer?
    Holgado, Esther
    Perez-Garcia, Jose
    Gion, Maria
    Cortes, Javier
    NPJ BREAST CANCER, 2018, 4
  • [7] Advances in targeting HER2-positive breast cancer
    Harbeck, Nadia
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (01) : 55 - 59
  • [8] Preoperative treatment of HER2-positive breast cancer
    Wysocki, Piotr J.
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (02): : 69 - 74
  • [9] Neoadjuvant treatment for HER2-positive breast cancer
    Takada, Masahiro
    Toi, Masakazu
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [10] Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
    Yin, Wenjin
    Wang, Yaohui
    Wu, Ziping
    Ye, Yumei
    Zhou, Liheng
    Xu, Shuguang
    Lin, Yanping
    Du, Yueyao
    Yan, Tingting
    Yang, Fan
    Zhang, Jie
    Liu, Qiang
    Lu, Jinsong
    CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3677 - 3685
12345